Respiratory ATP synthesis: the new generation of mycobacterial drug targets?

D. Bald, A. Koul

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Mycobacterium tuberculosis, the causative agent of tuberculosis, poses a global health challenge due to the emergence of drug-resistant strains. Recently, bacterial energy metabolism has come into focus as a promising new target pathway for the development of antimycobacterial drugs. This review summarizes our current knowledge on mycobacterial respiratory energy conversion, in particular, during the physiologically dormant state that is associated with latent or persistent tuberculosis infections. Targeting components of respiratory ATP production, such as type-2 NADH dehydrogenase or ATP synthase, is illustrated as an emerging strategy in the development of novel drugs. © 2010 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd.
Original languageEnglish
Pages (from-to)1-7
JournalFEMS Microbiology Letters
Volume308
DOIs
Publication statusPublished - 2010

Fingerprint

Dive into the research topics of 'Respiratory ATP synthesis: the new generation of mycobacterial drug targets?'. Together they form a unique fingerprint.

Cite this